| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 22.10.23 | HOOKIPA Pharma Inc.: HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023 | 239 | GlobeNewswire (Europe) | 42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line setting-doubling historical ORR reported with pembrolizumab... ► Artikel lesen | |
| 22.10.23 | Sutro Biopharma, Inc.: Sutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin (luvelta) from the Phase 1 Dose-Expansion Study in Endometrial Cancers at ESMO 2023 | 197 | GlobeNewswire (Europe) | - Luvelta demonstrated encouraging preliminary anti-tumor activity (29% response rate) in late-stage patients with recurrent/relapsed endometrial cancer with tumor proportion score (TPS) >25% FolRa... ► Artikel lesen | |
| 22.10.23 | Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant | 272 | GlobeNewswire (Europe) | Across all 86 heavily pretreated patients, the median PFS was 4.6 months with a CBR of 40%; in patients with ESR1 mutations at baseline, the median PFS was 5.6 months with a CBR of 52% In an analysis... ► Artikel lesen | |
| 22.10.23 | Revolution Medicines, Inc.: Revolution Medicines Presents Promising Clinical Activity and Safety Data from Phase 1/1b Trial of RMC-6236 | 329 | GlobeNewswire (Europe) | REDWOOD CITY, Calif., Oct. 22, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced... ► Artikel lesen | |
| 22.10.23 | Sanofi: Dupixent® (dupilumab) Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis (EoE) | 612 | GlobeNewswire (Europe) | Dupixent® (dupilumab) Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis (EoE)
Late-breaking presentation at ACG 2023 showed... ► Artikel lesen | |
| 22.10.23 | Agillic A/S: Agillic joins partner Immeo in supporting the 'Knæk Cancer' (fight cancer) fundraising campaign | 464 | GlobeNewswire (Europe) | Cancer affects one out of every three people in Denmark before the age of 75, making cancer something that touches most, if not every Dane. Whether as a patient, next of kin, friend, or colleague, we... ► Artikel lesen |
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| GAMESTOP | 3.304 |
| EVOTEC | 2.642 |
| TUI | 2.080 |
| NEL | 1.330 |
| BAYER | 1.153 |
| PLUG POWER | 1.148 |
| NVIDIA | 1.143 |
| RHEINMETALL | 1.063 |
| AMC ENTERTAINMENT | 1.038 |
| DEUTSCHE BANK | 967 |
| SIEMENS ENERGY | 938 |
| RENK GROUP | 875 |
| REDCARE PHARMACY | 728 |
| COMMERZBANK | 727 |
| HEIDELBERGER DRUCK | 702 |
| ALIBABA | 679 |
| VOLKSWAGEN | 675 |
| E.ON | 620 |
| BARRICK GOLD | 614 |
| BYD | 593 |
| RWE | 588 |
| TESLA | 566 |
| SIEMENS | 565 |
| DEUTSCHE LUFTHANSA | 563 |
| AIXTRON SE | 557 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
